Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine 
VPM1002 in HIV-Unexposed Newborn Infants in South Africa

Loxton, André G.; Knaul, Julia K.; Grode, Leander; Gutschmidt, Andrea; Meller, Christiane; Eisele, Bernd; Johnstone, Hilary; van der Spuy, Gian; Maertzdorf, Jeroen; Kaufmann, Stefan H. E.; Hesseling, Anneke C.; Walzl, Gerhard; Cotton, Mark F.

doi:10.1128/CVI.00439-16

Item

ITEM ACTIONSEXPORT

Add to Basket

Please note that a newer version of this item is available:
https://pure.mpg.de/pubman/item/item_2395322_4

DetailsSummary

Released

Journal Article

Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa

MPS-Authors

/persons/resource/persons82029

Maertzdorf, Jeroen
Department of Immunology, Max Planck Institute for Infection Biology, Max Planck Society;

/persons/resource/persons81969

Kaufmann, Stefan H. E.
Department of Immunology, Max Planck Institute for Infection Biology, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

Clin_Vaccine_Immunol_2017_24_e00439-16.pdf
(Publisher version), 2MB

Supplementary Material (public)

There is no public supplementary material available

Citation

Loxton, A. G., Knaul, J. K., Grode, L., Gutschmidt, A., Meller, C., Eisele, B., et al. (2017). Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Clinical and Vaccine Immunology, 24(2): e00439-16. doi: 10.1128/CVI.00439-16.

Cite as: https://hdl.handle.net/11858/00-001M-0000-002C-61A9-4

Abstract

There is no abstract available